Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Prospective Phenotyping for Genetic Subtypes of Early-onset Atrial Fibrillation

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a prospective, case-control study that seeks to learn about the role of genetics in early onset atrial fibrillation (AF) and if genetic testing can be used to improve how the investigators treat atrial fibrillation. The study will enroll 225 participants. Eligible participants will have undergone sequencing for arrhythmia and cardiomyopathy (CM) genes. Based on those results, participants will be recruited for an outpatient research visit with testing that includes cardiac MRI, rest/stress/signal-averaged ECGs, and cardiac monitoring. If an inherited arrhythmia/CM syndrome is diagnosed, guideline-directed changes to medical care will be recommended.

Who May Be Eligible (Plain English)

Who May Qualify: - Minors \>15 years - Adult \> 18 years - Able to provide written willing to sign a consent form - Previously enrolled in the Vanderbilt Atrial Fibrillation Registry (IVR#020669) - Atrial Fibrillation Ablation Registry (IRB#110881) - Early-onset Atrial Fibrillation Registry (IRB#201666) - Underwent whole genome sequencing/whole exome sequencing or clinical genetic testing and based on those results meets the genetic criteria for cases and controls as defined as a Cardiomyopathy (CM) Rare Variant (P/LP rare variant in CM gene, Arrhythmia Rare Variant (P/LP rare variant in arrhythmia gene), or a Control (no rare variant in CM, arrhythmia, or other Atrial Fibrillation gene). - Diagnosis of Atrial Fibrillation prior to age of 65 (\</=65) Who Should NOT Join This Trial: -Pregnant women Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Minors \>15 years * Adult \> 18 years * Able to provide written informed consent * Previously enrolled in the Vanderbilt Atrial Fibrillation Registry (IVR#020669) * Atrial Fibrillation Ablation Registry (IRB#110881) * Early-onset Atrial Fibrillation Registry (IRB#201666) * Underwent whole genome sequencing/whole exome sequencing or clinical genetic testing and based on those results meets the genetic criteria for cases and controls as defined as a Cardiomyopathy (CM) Rare Variant (P/LP rare variant in CM gene, Arrhythmia Rare Variant (P/LP rare variant in arrhythmia gene), or a Control (no rare variant in CM, arrhythmia, or other Atrial Fibrillation gene). * Diagnosis of Atrial Fibrillation prior to age of 65 (\</=65) Exclusion Criteria: -Pregnant women

Treatments Being Tested

OTHER

None/Observational Studies

This is an observational study and there is no intervention.

Locations (1)

Vanderbilt University Medical Center
Nashville, Tennessee, United States